Literature DB >> 26924046

Patients with primary membranous nephropathy are at high risk of cardiovascular events.

Taewoo Lee1, Vimal K Derebail2, Abhijit V Kshirsagar2, Yunro Chung3, Jason P Fine3, Shannon Mahoney2, Caroline J Poulton2, Sophia Lionaki4, Susan L Hogan2, Ronald J Falk2, Daniel C Cattran5, Michelle Hladunewich5, Heather N Reich5, Patrick H Nachman6.   

Abstract

Here we conducted a retrospective study to examine the risk of cardiovascular events (CVEs) relative to that of end-stage renal disease (ESRD) in patients with primary membranous nephropathy, in a discovery cohort of 404 patients. The cumulative incidence of CVEs was estimated in the setting of the competing risk of ESRD with risk factors for CVEs assessed by multivariable survival analysis. The observed cumulative incidences of CVEs were 4.4%, 5.4%, 8.2%, and 8.8% at 1, 2, 3, and 5 years respectively in the primary membranous nephropathy cohort. In the first 2 years after diagnosis, the risk for CVEs was similar to that of ESRD in the entire cohort, but exceeded it among patients with preserved renal function. Accounting for traditional risk factors and renal function, the severity of nephrosis at the time of the event (hazard ratio 2.1, 95% confidence interval 1.1 to 4.3) was a significant independent risk factor of CVEs. The incidence and risk factors of CVEs were affirmed in an external validation cohort of 557 patients with primary membranous nephropathy. Thus early in the course of disease, patients with primary membranous nephropathy have an increased risk of CVEs commensurate to, or exceeding that of ESRD. Hence, reduction of CVEs should be considered as a therapeutic outcome measure and focus of intervention in primary membranous nephropathy.
Copyright © 2016 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cardiovascular disease; glomerulonephritis; membranous nephropathy

Mesh:

Year:  2016        PMID: 26924046      PMCID: PMC6787915          DOI: 10.1016/j.kint.2015.12.041

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  28 in total

Review 1.  Predicting progression in membranous glomerulonephritis.

Authors:  D C Cattran; Y Pei; C Greenwood
Journal:  Nephrol Dial Transplant       Date:  1992       Impact factor: 5.992

Review 2.  Complications of the nephrotic syndrome and their treatment.

Authors:  R J Crew; J Radhakrishnan; G Appel
Journal:  Clin Nephrol       Date:  2004-10       Impact factor: 0.975

Review 3.  Nephrotic syndrome in adults.

Authors:  Richard P Hull; David J A Goldsmith
Journal:  BMJ       Date:  2008-05-24

4.  Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial.

Authors:  M Praga; V Barrio; G Fernández Juárez; J Luño
Journal:  Kidney Int       Date:  2007-03-21       Impact factor: 10.612

5.  Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis.

Authors:  Sean J Barbour; Allen Greenwald; Ognjenka Djurdjev; Adeera Levin; Michelle A Hladunewich; Patrick H Nachman; Susan L Hogan; Daniel C Cattran; Heather N Reich
Journal:  Kidney Int       Date:  2011-09-14       Impact factor: 10.612

6.  A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy.

Authors:  C Ponticelli; P Zucchelli; P Passerini; B Cesana; F Locatelli; S Pasquali; M Sasdelli; B Redaelli; C Grassi; C Pozzi
Journal:  Kidney Int       Date:  1995-11       Impact factor: 10.612

7.  Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria.

Authors:  M E Thomas; K P Harris; C Ramaswamy; J M Hattersley; D C Wheeler; Z Varghese; J D Williams; J Walls; J F Moorhead
Journal:  Kidney Int       Date:  1993-11       Impact factor: 10.612

Review 8.  Hyperlipidemia and thrombotic complications in patients with membranous nephropathy.

Authors:  Thomas L Nickolas; Jai Radhakrishnan; Gerald B Appel
Journal:  Semin Nephrol       Date:  2003-07       Impact factor: 5.299

9.  A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Canadian Glomerulonephritis Study Group.

Authors:  D C Cattran; C Greenwood; S Ritchie; K Bernstein; D N Churchill; W F Clark; P A Morrin; S Lavoie
Journal:  Kidney Int       Date:  1995-04       Impact factor: 10.612

10.  Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease.

Authors:  Li Wei; Thomas M MacDonald; Brian R Walker
Journal:  Ann Intern Med       Date:  2004-11-16       Impact factor: 25.391

View more
  16 in total

1.  Prophylactic Anticoagulation in Adult Patients with Nephrotic Syndrome.

Authors:  Judit Gordon-Cappitelli; Michael J Choi
Journal:  Clin J Am Soc Nephrol       Date:  2019-10-01       Impact factor: 8.237

Review 2.  Primary Membranous Nephropathy.

Authors:  William G Couser
Journal:  Clin J Am Soc Nephrol       Date:  2017-05-26       Impact factor: 8.237

3.  A Core Outcome Set for Trials in Glomerular Disease: A Report of the Standardized Outcomes in Nephrology-Glomerular Disease (SONG-GD) Stakeholder Workshops.

Authors:  Simon A Carter; Liz Lightstone; Dan Cattran; Allison Tong; Arvind Bagga; Sean J Barbour; Jonathan Barratt; John Boletis; Dawn J Caster; Rosanna Coppo; Fernando C Fervenza; Jürgen Floege; Michelle A Hladunewich; Jonathan J Hogan; A Richard Kitching; Richard A Lafayette; Ana Malvar; Jai Radhakrishnan; Brad H Rovin; Nicole Scholes-Robertson; Hernán Trimarchi; Hong Zhang; Samaya Anumudu; Yeoungjee Cho; Talia Gutman; Emma O'Lone; Andrea K Viecelli; Eric Au; Karolis Azukaitis; Amanda Baumgart; Amelie Bernier-Jean; Louese Dunn; Martin Howell; Angela Ju; Charlotte Logeman; Melissa Nataatmadja; Benedicte Sautenet; Ankit Sharma; Jonathan C Craig
Journal:  Clin J Am Soc Nephrol       Date:  2021-12-30       Impact factor: 8.237

Review 4.  Autoimmune-mediated renal disease and hypertension.

Authors:  Erika I Boesen; Rahul M Kakalij
Journal:  Clin Sci (Lond)       Date:  2021-09-17       Impact factor: 6.876

Review 5.  Advances in Pathogenesis of Idiopathic Membranous Nephropathy.

Authors:  Zhifeng Xu; Lu Chen; Huiling Xiang; Chun Zhang; Jing Xiong
Journal:  Kidney Dis (Basel)       Date:  2020-06-02

6.  Serum Albumin at Partial Remission Predicts Outcomes in Membranous Nephropathy.

Authors:  Taewoo Lee; Yunro Chung; Caroline J Poulton; Vimal K Derebail; Susan L Hogan; Heather N Reich; Ronald J Falk; Patrick H Nachman
Journal:  Kidney Int Rep       Date:  2020-03-04

7.  Primary Nephrotic Syndrome and Risks of ESKD, Cardiovascular Events, and Death: The Kaiser Permanente Nephrotic Syndrome Study.

Authors:  Alan S Go; Thida C Tan; Glenn M Chertow; Juan D Ordonez; Dongjie Fan; David Law; Leonid Yankulin; Janet M Wojcicki; Sijie Zheng; Kenneth K Chen; Farzien Khoshniat-Rad; Jingrong Yang; Rishi V Parikh
Journal:  J Am Soc Nephrol       Date:  2021-06-18       Impact factor: 14.978

8.  Comparison of prognostic, clinical, and renal histopathological characteristics of overlapping idiopathic membranous nephropathy and IgA nephropathy versus idiopathic membranous nephropathy.

Authors:  Xinxin Chen; Yu Chen; Keqing Shi; Yinqiu Lv; Huan Tong; Guangju Zhao; Chaosheng Chen; Bo Chen; Duo Li; Zhongqiu Lu
Journal:  Sci Rep       Date:  2017-09-13       Impact factor: 4.379

9.  Baseline proteinuria level is associated with prognosis in idiopathic membranous nephropathy.

Authors:  Xinxin Chen; Yu Chen; Xiaokai Ding; Ying Zhou; Yinqiu Lv; Duo Li; Bo Chen; Tianxin Chen; Chaosheng Chen
Journal:  Ren Fail       Date:  2019-11       Impact factor: 2.606

10.  Management of anticoagulation and antiplatelet therapy in patients with primary membranous nephropathy.

Authors:  Honghong Zou; Yebei Li; Gaosi Xu
Journal:  BMC Nephrol       Date:  2019-12-02       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.